Is ixazomi covered by medical insurance? What is the latest reimbursement policy?

IxazomibThe original drug has been approved by the National Medical Products Administration and has been marketed in China. It is sold under the name of Ixazomib Citrate Capsules (NINLARO/NINLARO). It has subsequently entered the scope of Class B medical insurance reimbursement through relevant regulations of the National Medical Insurance Administration. Reimbursement is limited to eligible patients. However, specific reimbursement policies and standards may vary depending on regions and policies.

Ixazomib is the first oral proteasome inhibitor to demonstrate clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma. The TOURMALINE-MM1 study showed that in patients with relapsed or refractory multiple myeloma, adding ixazomib to lenalidomide and dexamethasone significantly improved progression-free survival (PFS) compared with placebo plus lenalidomide and dexamethasone. Ixazomib in combination with lenalidomide and dexamethasone is the first all-oral triple therapy for patients with relapsed or refractory multiple myeloma.

For domestically marketed ixazomib original drugs, common capsule preparations may cost more than 10,000 yuan per box, which is relatively expensive. However, for ixazomib original drugs sold overseas, each box costs more than 10,000 U.S. dollars (the price may fluctuate due to exchange rates). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.